American Journal of Cardiology
Volume 105, Issue 6 , Pages 839-843 , 15 March 2010

Blunting of the Heart Rate Response to Adenosine and Regadenoson in Relation to Hyperglycemia and the Metabolic Syndrome

  • Fadi G. Hage, MD

      Affiliations

    • Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama
    • Section of Cardiology, Birmingham Veterans Administration Medical Center, Birmingham, Alabama
    • Corresponding Author InformationCorresponding author: Tel: 205-934-0406; fax: 205-934-0424
    • ,
  • Gilbert Perry, MD

      Affiliations

    • Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama
    • Section of Cardiology, Birmingham Veterans Administration Medical Center, Birmingham, Alabama
    • ,
  • Jaekyeong Heo, MD

      Affiliations

    • Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Ami E. Iskandrian, MD

      Affiliations

    • Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama

Received 29 August 2009 ,Revised 8 November 2009 ,Accepted 8 November 2009.

References 

  1. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–776
  2. Alberti C, Monopoli A, Casati C, Forlani A, Sala C, Nador B, et al. Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol. 1997;30:320–324
  3. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702
  4. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14:23–29
  5. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–658
  6. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI trial results. JACC Cardiol Img. 2008;1:307–316
  7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266
  8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  9. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26:1895–1901
  10. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:334–339
  11. Russell JW, Berent-Spillson A, Vincent AM, Freimann CL, Sullivan KA, Feldman EL. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis. 2008;30:420–429
  12. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13
  13. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51:1725–1733
  14. Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003;107:2894–2899
  15. Venkataraman R, Hage FG, Dorfman TA, Heo J, Aqel RA, de Mattos AM, et al. Relation between heart rate response to adenosine and mortality in patients with end-stage renal disease. Am J Cardiol. 2009;103:1159–1164
  16. Piccini JP, Horton JR, Shaw LK, Al-Khatib SM, Lee KL, Iskandrian AE, et al. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. Circ Cardiovasc Imaging. 2008;1:180–188
  17. Empana JP, Duciemetiere P, Balkau B, Jouven X. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. Eur Heart J. 2007;28:1149–1154
  18. Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol. 2008;102:40–46
  19. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–397

 Dr. Iskandrian has received grant support from and provided consultant services to Astellas Pharma US, Inc., Deerfield, Illinois.

PII: S0002-9149(09)02768-4

doi: 10.1016/j.amjcard.2009.11.042

American Journal of Cardiology
Volume 105, Issue 6 , Pages 839-843 , 15 March 2010

Article Tools

* Image Usage & Resolution